Expression Profile Analysis of Zinc Transporters (ZIP4, ZIP9, ZIP11, ZnT9) in Gliomas and their Correlation with IDH1 Mutation Status

  • Kang, Xing (School of Life Sciences, Northwest University) ;
  • Chen, Rong (School of Life Sciences, Northwest University) ;
  • Zhang, Jie (School of Life Sciences, Northwest University) ;
  • Li, Gang (Department of Neurosurgery, Tangdu Hospital of the Fourth Military Medical University) ;
  • Dai, Peng-Gao (School of Life Sciences, Northwest University) ;
  • Chen, Chao (School of Life Sciences, Northwest University) ;
  • Wang, Hui-Juan (School of Life Sciences, Northwest University)
  • Published : 2015.04.29


Background: Zinc transporters have been considered as essential regulators in many cancers; however, their mechanisms remain unknown, especially in gliomas. Isocitrate dehydrogenase 1(IDH1) mutation is crucial to glioma. This study aimed to investigate whether zinc transporters are correlated with glioma grade and IDH1 mutation status. Materials and Methods: IDH1 mutation status and mRNA expression of four zinc transporters (ZIP4, ZIP9, ZIP11, and ZnT9) were determined by subjecting a panel of 74 glioma tissue samples to quantitative real-time PCR and pyrosequencing. The correlations between the expression levels of these zinc transporter genes and the grade of glioma, as well as IDH1 mutation status, were investigated. Results: Among the four zinc transporter genes, high ZIP4 expression and low ZIP11 expression were significantly associated with higher grade (grades III and IV) tumors compared with lower grade (grades I and II) counterparts (p<0.0001). However, only ZIP11 exhibited weak correlation with IDH1 mutation status (p=0.045). Samples with mutations in IDH1 displayed higher ZIP11 expression than those without IDH1 mutations. Conclusions: This finding indicated that zinc transporters may interact with IDH1 mutation by direct modulation or action in some shared pathways or genes to promote the development of glioma. Zinc transporters may play an important role in glioma. ZIP4 and ZIP11 are promising molecular diagnostic markers and novel therapeutic targets. Nevertheless, the detailed biological function of zinc transporters and the mechanism of the potential interaction between ZIP11 and IDH1 mutation in gliomagenesis should be further investigated.


Glioma-isocitrate dehydrogenase 1 (IDH1);zinc transporter-expression


  1. Balss J, Meyer J, Mueller W, et al (2008). Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathologica, 116, 597-602.
  2. Bleeker FE, Molenaar RJ, Leenstra S (2012). Recent advances in the molecular understanding of glioblastoma. J Neuro-Oncol, 108, 11-27.
  3. Cancer Genome Atlas Research Network (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 455, 1061-8.
  4. Chen QG, Zhang Z, Yang Q, et al (2012). The role of zinc transporter ZIP4 in prostate carcinoma. Urologic Oncol, 30, 906-11.
  5. Costello LC, Franklin RB (2013). A review of the current status and concept of the emerging implications of zinc and zinc transporters in the development of pancreatic cancer. Pancreat Disord Ther, Suppl 4.
  6. Costello LC, Levy BA, Desouki MM, et al (2011). Decreased zinc and downregulation of ZIP3 zinc uptake transporter in the development of pancreatic adenocarcinoma. Cancer Biol Ther, 12, 297-303.
  7. Dubbink HJ, Taal W, van Marion R, et al (2009). IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology, 73, 1792-5.
  8. Ducray F, Marie Y, Sanson M (2009). IDH1 and IDH2 mutations in gliomas. New England J Med, 360, 2248-9.
  9. Duncan CG, Barwick BG, Jin G, et al (2012). A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. Genome Res, 22, 2339-55.
  10. Franklin RB, Levy BA, Zou J, et al (2012). ZIP14 zinc transporter downregulation and zinc depletion in the development and progression of hepatocellular cancer. J Gastrointest Cancer, 43, 249-57.
  11. Franz MC, Anderle P, Burzle M, et al (2013). Zinc transporters in prostate cancer. Mol Aspects Med, 34, 735-41.
  12. Kambe T, Hashimoto A, Fujimoto S (2014). Current understanding of ZIP and ZnT zinc transporters in human health and diseases. Cell Mol Life Sci, 71, 3281-95.
  13. Kim I, Kim CH, Seo GH, et al (2008). Inhibitory effect of zinc on hypoxic HIF-1 activation in astrocytes. Neuroreport, 19, 1063-6.
  14. Krell D, Mulholland P, Frampton AE, et al (2013). IDH mutations in tumorigenesis and their potential role as novel therapeutic targets. Future Oncol (London, England), 9, 1923-35.
  15. Wang J-B, Dong D-F, Wang M-D, et al (2014). IDH1 overexpression induced chemotherapy resistance and IDH1 mutation enhanced chemotherapy sensitivity in glioma cells in vitro and in vivo. Asian Pac J Cancer Prev, 15, 427-32.
  16. Li M, Zhang Y, Liu Z, et al (2007). Aberrant expression of zinc transporter ZIP4 (SLC39A4) significantly contributes to human pancreatic cancer pathogenesis and progression. P Natl Acad Sci USA, 104, 18636-41.
  17. Lichten LA, Cousins RJ (2009a). Mammalian zinc transporters: nutritional and physiologic regulation. Ann Rev Nutr, 29, 153-76.
  18. Lichten LA, Cousins RJ (2009b). Mammalian zinc transporters: nutritional and physiologic regulation. Ann Rev Nutr, 29, 153-76.
  19. Lin Y, Chen Y, Wang Y, et al (2013). ZIP4 is a novel molecular marker for glioma. Neuro Oncol, 15, 1008-16.
  20. Lonnerdal B (2007). Trace element transport in the mammary gland. Ann Rev Nutr, 27, 165-77.
  21. Maret W (2013). Zinc and human disease. Met Ions Life Sci, 13, 389-414.
  22. Martin AB, Aydemir TB, Guthrie GJ, et al (2013). Gastric and colonic zinc transporter ZIP11 (Slc39a11) in mice responds to dietary zinc and exhibits nuclear localization. J Nutr, 143, 1882-8.
  23. Masica DL, Karchin R (2011). Correlation of somatic mutation and expression identifies genes important in human glioblastoma progression and survival. Cancer Res, 71, 4550-61.
  24. Michalczyk A, Allen J, Blomeley R, et al (2002). Constitutive expression of hZnT4 zinc transporter in human breast epithelial cells. Biochem J, 364, 105-13.
  25. Nardinocchi L, Pantisano V, Puca R, et al (2010). Zinc downregulates HIF-1alpha and inhibits its activity in tumor cells in vitro and in vivo. PloS One, 5, 15048.
  26. Parsons DW, Jones S, Zhang X, et al (2008). An integrated genomic analysis of human glioblastoma multiforme. Science, 321, 1807-12.
  27. Setty P, Hammes J, Rothamel T, et al (2010). A pyrosequencingbased assay for the rapid detection of IDH1 mutations in clinical samples. J Mol Diagnostics, 12, 750-6.
  28. Taylor KM, Vichova P, Jordan N, et al (2008). ZIP7-mediated intracellular zinc transport contributes to aberrant growth factor signaling in antihormone-resistant breast cancer cells. Endocrinology, 149, 4912-20.
  29. Turcan S, Rohle D, Goenka A, et al (2012). IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature, 483, 479-83.
  30. Watanabe T, Nobusawa S, Kleihues P, et al (2009). IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol, 174, 1149-53.
  31. Zhao S, Lin Y, Xu W, et al (2009). Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science, 324, 261-5.

Cited by

  1. Expression of the zinc importer protein ZIP9/SLC39A9 in glioblastoma cells affects phosphorylation states of p53 and GSK-3β and causes increased cell migration vol.29, pp.6, 2016,
  2. Zinc and zinc-containing biomolecules in childhood brain tumors vol.94, pp.11, 2016,
  3. SLC39A4 expression is associated with enhanced cell migration, cisplatin resistance, and poor survival in non-small cell lung cancer vol.7, pp.1, 2017,
  4. Zinc Transporter Proteins pp.1573-6903, 2017,